Wnt-C59
(Synonyms: PORCN酶活性和WNT抑制剂(WNT-C59),C59) 目录号 : GC13658
Wnt-C59是Mboat（膜结合的O-酰脱糖酶）家族成员Porcupine（Porcn）的高度有效抑制剂，IC50值为74pM，能够抑制Wnt信号传导。
Cas No.:1243243-89-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Wnt-C59 is a highly potent inhibitor of Porcupine (Porcn), a member of the Mboat (membrane-bound O-acyl deglycosylase) family, with an IC50 value of 74pM, and can inhibit Wnt signaling[1]. The Wnt signaling pathway is a complex network of proteins whose functions are most commonly seen in embryonic development and cancer, but are also involved in normal physiological processes in adult animals[2]. Wnt-C59 has the potential to eradicate cancer stem cells (CSCs) in human tumors[3]. Wnt-C59 can be used to induce human pluripotent stem cells (IPSCs) to differentiate into cortical motor neurons (CMNs) or their progenitors[4].
In vitro, Wnt-C59 (0.01, 1μM) treatment of NIH 3T3 fibroblasts for 48h significantly induced the expression of genes related to hypertrophy (BNP) and fibrosis (COL1 and COL3) in the cells[5]. Wnt-C59 (10μM) treatment of human fetal liver progenitor cells (HFLPC) significantly inhibited cell migration and proliferation induced by Wnt3a and Wnt5a[6].
In vivo, Wnt-C59 (5mg/kg) was orally treated for 4 weeks in cardiac hypertrophy model mice, which significantly improved the cardiac function and survival rate of mice, and attenuated the transverse aortic constriction (TAC)-induced cardiac mass, increase in cardiomyocyte cross-sectional area, cardiac fibrosis, cardiomyocyte apoptosis, and expression of hypertrophic biomarkers β-MHC, ANP, and BNP[7]. Wnt-C59 (40, 60mg/kg) was intraperitoneally treated in mice with endotoxin-induced sepsis, which significantly improved the survival rate of mice and reduced the lethality and plasma levels of proinflammatory cytokines and organ damage biomarkers[8].
References:
[1] Shah K, Panchal S, Patel B. Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway[J]. Pharmacological research, 2021, 167: 105532.
[2] Anastas J N, Moon R T. WNT signalling pathways as therapeutic targets in cancer[J]. Nature Reviews Cancer, 2013, 13(1): 11-26.
[3] Cheng Y, Phoon Y P, Jin X, et al. Wnt-C59 arrests stemness and suppresses growth of nasopharyngeal carcinoma in mice by inhibiting the Wnt pathway in the tumor microenvironment[J]. Oncotarget, 2015, 6(16): 14428.
[4] Motono M, Ioroi Y, Ogura T, et al. WNT-C59, a small-molecule WNT inhibitor, efficiently induces anterior cortex that includes cortical motor neurons from human pluripotent stem cells[J]. Stem cells translational medicine, 2016, 5(4): 552-560.
[5] Paul M A, Wainwright C L, Hector E E, et al. Short‐Term Oral Administration of the Porcupine Inhibitor, Wnt‐c59, Improves the Structural and Functional Features of Experimental HFpEF[J]. Pharmacology Research & Perspectives, 2025, 13(1): e70054.
[6] Liu Z, Kuna V K, Xu B, et al. Wnt ligands 3a and 5a regulate proliferation and migration in human fetal liver progenitor cells[J]. Translational Gastroenterology and Hepatology, 2021, 6.
[7] Zhao Z, Liu H, Li Y, et al. Wnt-C59 attenuates pressure overload-induced cardiac hypertrophy via interruption of wnt pathway[J]. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 2020, 26: e923025-1.
[8] Jang J, Song J, Sim I, et al. Wnt-Signaling Inhibitor Wnt-C59 suppresses the cytokine upregulation in multiple organs of lipopolysaccharide-induced endotoxemic mice via reducing the interaction between β-Catenin and NF-κB[J]. International Journal of Molecular Sciences, 2021, 22(12): 6249.
Wnt-C59是Mboat（膜结合的O-酰脱糖酶）家族成员Porcupine（Porcn）的高度有效抑制剂，IC50值为74pM，能够抑制Wnt信号传导[1]。Wnt信号通路是一个复杂的蛋白质作用网络，其功能最常见于胚胎发育和癌症，但也参与成年动物的正常生理过程[2]。Wnt-C59具有根除人类肿瘤中癌症干细胞（CSC）的潜力[3]。Wnt-C59能够用于诱导人多能干细胞（IPSC）分化为皮质运动神经元（CMN）或其祖细胞[4]。
在体外，Wnt-C59（0.01, 1μM）处理NIH 3T3成纤维细胞48h，显著诱导了细胞中与肥大有关的基因（BNP）和纤维化（COL1和COL3）的表达[5]。Wnt-C59（10μM）处理人胎儿肝祖细胞（HFLPC），显著抑制了Wnt3a和Wnt5a诱导的细胞迁移和增殖[6]。
在体内，Wnt-C59（5mg/kg）通过口服治疗心脏肥大模型小鼠4周，显著改善了小鼠的心脏功能并提高了其存活率，减弱了横向主动脉收缩（TAC）手术诱导的心脏质量、心肌细胞横截面积的增加、心脏纤维化、心肌细胞凋亡以及肥大性生物标志物β-MHC、ANP和BNP的表达[7]。Wnt-C59（40，60mg/kg）通过腹腔注射治疗内毒素诱导的败血症小鼠，显著提高了小鼠的存活率，降低了促炎细胞因子和器官破坏生物标志物的致死性和血浆水平[8]。
| Cell experiment [1]: | |
Cell lines | NIH 3T3 fibroblasts |
Preparation Method | NIH 3T3 fibroblasts were seeded in 6 well plates (50000 cells per well) and treated with Wnt-C59 (0.01μM and 1μM) for 48h and the expression of genes related to hypertrophy (BNP) and fibrosis (Col1 and Col3) measured in cell lysates. |
Reaction Conditions | 0.01, 1μM; 48h |
Applications | Wnt-C59 induced the expression of BNP and both Col1 and Col3 in Fibroblasts. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice |
Preparation Method | Mice were divided into 4 groups: sham, sham+Wnt-C59, transverse aortic constriction (TAC), and TAC+Wnt-C59. Briefly, mice were anesthetized with isoflurane (2%) and a sternotomy was performed to visualize the aortic arch. Then, 7-0 polypropylene suture was used to ligate the aortic arch with a 27G needle as a space holder, which was subsequently removed. The same surgical procedures except for the ligation of the aorta were performed to animals in the sham group. Wnt-C59 was dissolved in saline and administered daily by oral gavage (5mg/kg/day) for experimental groups for 4 weeks. Cardiac function was measured by transthoracic echocardiography using GE vivid 8-dimension ultrasound 4 weeks after TAC surgery. Then mice were anesthetized by isoflurane overdose and hearts were harvested. |
Dosage form | 5mg/kg; for 4 weeks; p.o. |
Applications | Wnt-C59 significantly improved cardiac function and enhanced survival of mice subjected to TAC surgery. Histologically, Wnt-C59 attenuated TAC-induced increase in heart mass, cross-section area of cardiomyocyte, cardiac fibrosis, cardiomyocyte apoptosis, and expression of the hypertrophic biomarkers β-MHC, ANP, and BNP. |
References: | |
| Cas No. | 1243243-89-1 | SDF | |
| 别名 | PORCN酶活性和WNT抑制剂(WNT-C59),C59 | ||
| 化学名 | 2-[4-(2-methylpyridin-4-yl)phenyl]-N-(4-pyridin-3-ylphenyl)acetamide | ||
| Canonical SMILES | CC1=NC=CC(=C1)C2=CC=C(C=C2)CC(=O)NC3=CC=C(C=C3)C4=CN=CC=C4 | ||
| 分子式 | C25H21N3O | 分子量 | 379.45 |
| 溶解度 | ≥ 18.95mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6354 mL | 13.177 mL | 26.3539 mL |
| 5 mM | 0.5271 mL | 2.6354 mL | 5.2708 mL |
| 10 mM | 0.2635 mL | 1.3177 mL | 2.6354 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet